GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti reminded investors of the August 3, 2026 deadline to file lead plaintiff applications in a securities class action against GeneDx Holdings. The lawsuit alleges the company failed to disclose material information, leading to a 49.2% stock drop after missing revenue estimates and lowering FY guidance to $475-$490 million.
Key figures
- Guidance
- FY revenue $475M-$490M, lowered from $540M-$550M
- Impairment loss
- $31.2 million
- Stock decline percent
- 49.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.